U.S. markets open in 7 hours 10 minutes
  • S&P Futures

    4,133.00
    +5.25 (+0.13%)
     
  • Dow Futures

    33,736.00
    +27.00 (+0.08%)
     
  • Nasdaq Futures

    13,760.25
    +10.00 (+0.07%)
     
  • Russell 2000 Futures

    2,241.70
    +13.40 (+0.60%)
     
  • Crude Oil

    61.89
    +0.46 (+0.75%)
     
  • Gold

    1,786.30
    +4.30 (+0.24%)
     
  • Silver

    26.19
    +0.01 (+0.04%)
     
  • EUR/USD

    1.2029
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    18.71
    +1.21 (+6.91%)
     
  • GBP/USD

    1.3858
    +0.0016 (+0.11%)
     
  • USD/JPY

    107.9140
    -0.0460 (-0.04%)
     
  • BTC-USD

    48,948.19
    -5,319.69 (-9.80%)
     
  • CMC Crypto 200

    1,115.19
    -127.87 (-10.29%)
     
  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     
  • Nikkei 225

    29,020.63
    -167.54 (-0.57%)
     

Tauriga Sciences Inc. Completes Initial Production Run of its Proprietary CBD Infused, Peanut Butter Flavor Pet Treat

  • Oops!
    Something went wrong.
    Please try again later.
Tauriga Sciences
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

02_25 9_35am EST PR Image

Image of Tauri-Pet™ Pouch (30 treats)
Image of Tauri-Pet™ Pouch (30 treats)
Image of Tauri-Pet™ Pouch (30 treats)


The Company Expects its Tauri-Pet™ Inventory to Arrive, at its E-Commerce Fulfillment Facility, Within 2-3 Weeks

NEW YORK, NY, Feb. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has completed the initial production run of its proprietary CBD infused, peanut butter flavor pet treat, branded as: Tauri-Pet™. This product is comprised of square shaped, peanut butter flavor, CBD infused dog treats (5mg CBD per treat) – 30 treats per Tauri-Pet™ pouch (150mg CBD total). The proprietary Tauri-Pet™ formulation incorporates the following features: full spectrum CBD, all-natural flavor, premium quality, and made in the USA.

The U.S. pet treat market is presently estimated at $7 billion - $10 billion annually, driven by CBD & Other Ingredient trends. The Company plans to develop additional versions of its Tauri-Pet™ product line in the future. The commercial launch of this new product offering will take place via the Company’s E-Commerce website (www.taurigum.com) and potential distribution partners.

Link to Tauri-Pet™ on E-Commerce Website (Coming Soon!)

https://taurigum.com/products/cbd-dog-treats

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.

The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @sethsms47

Twitter: @SethMShaw

Corp. Website: www.tauriga.com

E-Commerce Website: www.taurigum.com

Attachment